DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

Sponsor

Ophthalmic Consultants of the Capital Region (Other)

Overall Status

Unknown status

CT.gov ID

NCT04362241

Collaborator

(none)

Enrollment

Location

Arms

18.8

Anticipated Duration (Months)

1.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The complicated schedules for administering topical steroid eye drops combined with forgetfulness and physical difficulties instilling the drops may compromise compliance; which in turn could increase the risk for secondary complications such as PME post-cataract surgery, especially in a high-risk diabetic population. Dextenza, a sustained- release steroid insert, could help preclude adherence difficulties and provide better bioavailability, being as effective as, or more effective than steroid drops in preventing PME. The aim of this study is to assess the incidence of PME in diabetic patients undergoing cataract surgery when comparing the Dextenza insert to topical prednisolone acetate 1% drops.

Condition or Disease	Intervention/Treatment	Phase
Retinopathy, Diabetic	Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]	Phase 4

Detailed Description

This prospective, open-label, single-center, randomized, fellow-eye, investigator-sponsored clinical study seeks to investigate the incidence of PME in diabetic patients with any level of background diabetic retinopathy undergoing cataract surgery treated with a 0.4mg dexamethasone intracanalicular insert when compared to standard of care prednisolone acetate 1% QID/1 week, TID/ 1 week, BID/ 1 week, QD/1 week. Topical NSAIDs will not be used in this study and all patients will receive an intracameral injection of moxifloxacin at the end of the surgical procedure. After screening a patient for inclusion and exclusion criteria, and gaining informed consent, each eye will undergo cataract surgery on separate days. The second eye will be operated on within 60 days of the first eye's surgery. One eye will be randomized to receive the dexamethasone insert using a coin flip. The other eye will be prescribed a prednisolone acetate 0.1% eye drop QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week regimen. The dexamethasone insert will be placed 2-4 days before surgery (Day -4 to Day-2) and those randomized to receive prednisolone acetate will start 2-4 days before surgery. After surgery, each eye will be followed for a period of approximately 60 days, consisting of four post-op follow-up visits (eight total post-op visits per patient). Primary and secondary endpoints will be assessed alongside standard-of-care procedures at all study visits . Adjusting for the enrollment period, the study will last a total of approximately 12 months.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

30 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

This prospective study will use a fellow-eye design for 30 participants, summing to 60 eyes total. All eyes will receive cataract surgery. Per participant, one eye will be randomized to receive DEXTENZA® insertion at the end of the surgery, while the other eye will be assigned to a standard of care prednisolone acetate 1% eye drop regimen.This prospective study will use a fellow-eye design for 30 participants, summing to 60 eyes total. All eyes will receive cataract surgery. Per participant, one eye will be randomized to receive DEXTENZA® insertion at the end of the surgery, while the other eye will be assigned to a standard of care prednisolone acetate 1% eye drop regimen.

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

DEXTENZA VS. PREDNISOLONE ACETATE 1% in the Incidence of Pseudophakic Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery

Actual Study Start Date :

Aug 7, 2020

Anticipated Primary Completion Date :

Feb 1, 2022

Anticipated Study Completion Date :

Mar 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Dextenza Sustained release Dexamethasone 0.4mg	Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE] Prednisolone Acetate 1% ophthalmic drops Other Names: Prednisolone Acetate 1%
Active Comparator: Prednisolone Acetate 1% Prednisolone Acetate Ophthalmic drops	Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE] Prednisolone Acetate 1% ophthalmic drops Other Names: Prednisolone Acetate 1%

Arm

Intervention/Treatment

Experimental: Dextenza

Sustained release Dexamethasone 0.4mg

Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]

Prednisolone Acetate 1% ophthalmic drops

Other Names:

Prednisolone Acetate 1%

Active Comparator: Prednisolone Acetate 1%

Prednisolone Acetate Ophthalmic drops

Drug: Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]

Prednisolone Acetate 1% ophthalmic drops

Other Names:

Prednisolone Acetate 1%

Outcome Measures

Primary Outcome Measures

To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. [7 days]
Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 7 on Optical Coherence Tomography at Day 7 by a masked grader.
To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. [30 days]
Percentage of eyes that developed post-surgical PME in each group measured on optical coherence tomography at Day 30 by a masked grader.
To measure the effect of 0.4mg dexamethasone intracanalicular insert in preventing PME in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1% as measure. [60 days]
Percentage of eyes that developed post-surgical PME in each group measured on fluorescein angiography at Day 60 and on optical coherence tomography at Day 60 by a masked grader.

Secondary Outcome Measures

Incidence of central subfield thickness (CST) at Day 7 post op as seen on optical coherence tomography (OCT) [7days]
Mean central subfield thickness (CST) at Day 7 post op in each group and comparison between groups.
Incidence of central subfield thickness (CST) at Day 7 post op as seen on optical coherence tomography (OCT) [30 days]
Mean central subfield thickness (CST) at Day 30 post op in each group and comparison between groups.
Incidence of central subfield thickness (CST) at Day 60 post op as seen on optical coherence tomography (OCT) [60 days]
Mean central subfield thickness (CST) at Day 60 post op in each group and comparison between groups.
To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. [7 days]
Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups.
To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. [30 days]
Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups.
To measure the change in CST inflammation outcomes and in diabetic patients as seen on optical coherence tomography (OCT), Dextenza compared to topical prednisolone acetate 1%. [60 days]
Mean change in CST from Baseline at Day 7, Day 30 and Day 60 and comparison between groups.
To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. [7 days]
Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 7 post op
To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. [30 days]
Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 30 post op
To measure the effect of 0.4mg dexamethasone intracanalicular insert in vision in diabetic patients undergoing cataract surgery when compared to topical prednisolone acetate 1%. [60 days]
Difference of mean ETDRS Best Corrected Visual Acuity (BCVA) between groups at Day 60 post op
Difference patients with absence of anterior chamber (AC) cells at Day 7 post op [7 days]
Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 7
Difference patients with absence of anterior chamber (AC) cells at Day 30 post op [30 days]
Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 30
Difference patients with absence of anterior chamber (AC) cells at Day 60 post op [30 days]
Percentage of patients who had absence of Anterior Chamber (AC) cells at Day 60
Self reported patient experience of comfort [60 days]
Self-reported patient experience of comfort (right eye vs. left eye) at Day 60.
Rescue Therapy [60 days]
Percentage of eyes rescued in each group.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Binocular
18 years old
Any level of Background Diabetic Retinopathy
Cataract surgery candidate in each eye
Pre-operative OCT and Fluorescein Angiography showing no Macular edema

Exclusion Criteria:

Participant cannot complete second eye operation within 60 days of the first cataract surgery
Maintains regular use of systemic or ocular steroids at time of enrollment
Maintains regular use of systemic or ocular non-steroidal anti-inflammatory drugs at time of enrollment
Anterior chamber cells present at time of enrollment
Recent febrile illness that precludes or delays participation for 90 days
Pregnancy or lactation
Known allergy to dexamethasone
Known allergy to prednisolone
Preexisting retinal disease including uveitis, nondiabetic retinal disease, choroidal disorders, diabetic macular edema.
Posterior capsule rupture or other intraoperative complication in first eye operated on
Amblyopia
Anti-VEGF injections within 6 months prior to surgery day.
Intraocular steroid injection within 6 months prior to surgery day.
Intraocular surgeries within 6 months prior to surgery day.
Laser photocoagulation within 30 days prior to surgery day.
Any type of eye inflammation
Any punctum inflammation or dacryocystitis